|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2, Inc., Danville, Calif. |
Geänderte antikörper.
|
|
US6218525B1
(en)
|
1988-02-25 |
2001-04-17 |
The General Hospital Corporation |
Nucleic acid encoding CD28
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US6685941B1
(en)
|
1988-11-23 |
2004-02-03 |
The Regents Of The University Of Michigan |
Methods of treating autoimmune disease via CTLA-4Ig
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6291159B1
(en)
|
1989-05-16 |
2001-09-18 |
Scripps Research Institute |
Method for producing polymers having a preselected activity
|
|
US5580756A
(en)
|
1990-03-26 |
1996-12-03 |
Bristol-Myers Squibb Co. |
B7Ig fusion protein
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US7063943B1
(en)
|
1990-07-10 |
2006-06-20 |
Cambridge Antibody Technology |
Methods for producing members of specific binding pairs
|
|
US6172197B1
(en)
|
1991-07-10 |
2001-01-09 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
CA2095633C
(en)
|
1990-12-03 |
2003-02-04 |
Lisa J. Garrard |
Enrichment method for variant proteins with altered binding properties
|
|
US5871907A
(en)
|
1991-05-15 |
1999-02-16 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US6887471B1
(en)
*
|
1991-06-27 |
2005-05-03 |
Bristol-Myers Squibb Company |
Method to inhibit T cell interactions with soluble B7
|
|
US5844095A
(en)
|
1991-06-27 |
1998-12-01 |
Bristol-Myers Squibb Company |
CTLA4 Ig fusion proteins
|
|
KR100238712B1
(ko)
|
1991-06-27 |
2000-01-15 |
스티븐 비. 데이비스 |
씨티엘에이4 수용체,그를 함유한 연합단백질 및 그의 용도
|
|
US5851795A
(en)
|
1991-06-27 |
1998-12-22 |
Bristol-Myers Squibb Company |
Soluble CTLA4 molecules and uses thereof
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
US5733743A
(en)
|
1992-03-24 |
1998-03-31 |
Cambridge Antibody Technology Limited |
Methods for producing members of specific binding pairs
|
|
US5773253A
(en)
|
1993-01-22 |
1998-06-30 |
Bristol-Myers Squibb Company |
MYPPPY variants of CTL A4 and uses thereof
|
|
US6482919B2
(en)
|
1993-02-01 |
2002-11-19 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
WO1994029351A2
(en)
|
1993-06-16 |
1994-12-22 |
Celltech Limited |
Antibodies
|
|
US6084067A
(en)
|
1993-07-26 |
2000-07-04 |
Dana-Farber Cancer Institute |
CTLA4/CD28 ligands and uses therefor
|
|
US5942607A
(en)
|
1993-07-26 |
1999-08-24 |
Dana-Farber Cancer Institute |
B7-2: a CTLA4/CD28 ligand
|
|
US6130316A
(en)
|
1993-07-26 |
2000-10-10 |
Dana Farber Cancer Institute |
Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
|
|
US6218510B1
(en)
|
1994-03-02 |
2001-04-17 |
Brigham & Woman's Hospital |
B7-1 and B7-2 polypeptides
|
|
US6713279B1
(en)
|
1995-12-07 |
2004-03-30 |
Diversa Corporation |
Non-stochastic generation of genetic vaccines and enzymes
|
|
US6750334B1
(en)
|
1996-02-02 |
2004-06-15 |
Repligen Corporation |
CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
|
|
US20030171551A1
(en)
|
1997-01-31 |
2003-09-11 |
Joseph D. Rosenblatt |
Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
|
|
US6294170B1
(en)
|
1997-08-08 |
2001-09-25 |
Amgen Inc. |
Composition and method for treating inflammatory diseases
|
|
US6730512B2
(en)
|
1997-04-09 |
2004-05-04 |
Amdl, Inc. |
Combination immunogene therapy
|
|
ES2231991T3
(es)
|
1997-06-11 |
2005-05-16 |
Borean Pharma A/S |
Modulo de trimerizacion.
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US5891432A
(en)
|
1997-07-29 |
1999-04-06 |
The Immune Response Corporation |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
|
|
PT1068241E
(pt)
|
1998-04-02 |
2007-11-19 |
Genentech Inc |
Variantes de anticorpos e respectivos fragmentos
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9823071D0
(en)
|
1998-10-21 |
1998-12-16 |
Affibody Technology Ab |
A method
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
|
AU779395B2
(en)
|
1999-04-30 |
2005-01-20 |
Institut De Recherche Cliniques De Montreal (Ircm) |
Mutant human CD80 and compositions for and methods of making and using the same
|
|
GB9917027D0
(en)
|
1999-07-20 |
1999-09-22 |
Affibody Technology Sweeden Ab |
In vitro selection and optional identification of polypeptides using solid support carriers
|
|
JP4737905B2
(ja)
|
1999-09-21 |
2011-08-03 |
ジェネティクス インスティテュート，エルエルシー |
Ｇｌ５０分子およびその使用
|
|
IL150571A0
(en)
|
2000-01-03 |
2003-02-12 |
Tr Associates L L C |
Novel chimeric proteins and methods for using the same
|
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
DE60104282T2
(de)
|
2000-05-26 |
2005-10-13 |
Bristol-Myers Squibb Co. |
Lösliche mutante ctla4 moleküle und deren verwendung
|
|
US7094874B2
(en)
|
2000-05-26 |
2006-08-22 |
Bristol-Myers Squibb Co. |
Soluble CTLA4 mutant molecules
|
|
CA2411828A1
(en)
|
2000-06-23 |
2002-01-03 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
US7183376B2
(en)
|
2000-06-23 |
2007-02-27 |
Maxygen, Inc. |
Variant B7 co-stimulatory molecules
|
|
WO2004029197A2
(en)
|
2001-06-22 |
2004-04-08 |
Maxygen, Inc. |
Co-stimulatory molecules
|
|
US20020164600A1
(en)
|
2000-06-28 |
2002-11-07 |
Gordon Freeman |
PD-L2 molecules: novel PD-1 ligands and uses therefor
|
|
ATE401909T1
(de)
|
2000-07-03 |
2008-08-15 |
Bristol Myers Squibb Co |
Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
|
|
US20040022787A1
(en)
|
2000-07-03 |
2004-02-05 |
Robert Cohen |
Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
|
|
US6635750B1
(en)
|
2000-07-20 |
2003-10-21 |
Millennium Pharmaceuticals, Inc. |
B7-H2 nucleic acids, members of the B7 family
|
|
ATE390931T1
(de)
|
2001-05-23 |
2008-04-15 |
Bristol Myers Squibb Co |
Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
|
|
US7553939B2
(en)
|
2001-06-29 |
2009-06-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
T cell regulatory genes and methods of use thereof
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
WO2003042402A2
(en)
|
2001-11-13 |
2003-05-22 |
Dana-Farber Cancer Institute, Inc. |
Agents that modulate immune cell activation and methods of use thereof
|
|
US7235631B2
(en)
|
2002-02-07 |
2007-06-26 |
Mayo Foundation For Medical Education And Research |
ICOS mutants
|
|
PT1553966E
(pt)
*
|
2002-10-03 |
2012-10-22 |
Wyeth Corp |
Péptidos de fusão que compreendem os polipéptidos e7 e e6 do vírus do papiloma humano e as composições imunogénicas dos mesmos
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
CN103833854B
(zh)
|
2002-12-16 |
2017-12-12 |
健泰科生物技术公司 |
免疫球蛋白变体及其用途
|
|
ES2354610T5
(es)
|
2002-12-23 |
2020-09-14 |
Bristol Myers Squibb Co |
Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
|
|
EP1591527B1
(en)
|
2003-01-23 |
2015-08-26 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human pd-1
|
|
JP2007501243A
(ja)
|
2003-08-04 |
2007-01-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
可溶性ｃｔｌａ４分子を用いる心臓血管疾患の治療方法
|
|
BRPI0507169A
(pt)
|
2004-02-02 |
2007-06-26 |
Ambrx Inc |
polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
|
|
WO2005100402A1
(en)
|
2004-04-13 |
2005-10-27 |
F.Hoffmann-La Roche Ag |
Anti-p-selectin antibodies
|
|
JP2008505174A
(ja)
|
2004-07-15 |
2008-02-21 |
ゼンコー・インコーポレイテッド |
最適化Ｆｃ変異体
|
|
WO2006091231A2
(en)
|
2004-07-21 |
2006-08-31 |
Ambrx, Inc. |
Biosynthetic polypeptides utilizing non-naturally encoded amino acids
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
NZ555353A
(en)
|
2004-11-22 |
2009-12-24 |
Anaphore Inc |
TNF antagonists
|
|
US7385028B2
(en)
|
2004-12-22 |
2008-06-10 |
Ambrx, Inc |
Derivatization of non-natural amino acids and polypeptides
|
|
WO2006108035A1
(en)
|
2005-04-06 |
2006-10-12 |
Bristol-Myers Squibb Company |
Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules
|
|
JP5508716B2
(ja)
|
2005-11-08 |
2014-06-04 |
アンブルックス，インコーポレイテッド |
非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤
|
|
JP5096369B2
(ja)
|
2005-12-20 |
2012-12-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
組成物および組成物の製造方法
|
|
CA2663083A1
(en)
|
2006-09-08 |
2008-03-13 |
Ambrx, Inc. |
Modified human plasma polypeptide or fc scaffolds and their uses
|
|
GB0620934D0
(en)
|
2006-10-20 |
2006-11-29 |
Cambridge Antibody Tech |
Protein variants
|
|
US8907065B2
(en)
|
2006-12-15 |
2014-12-09 |
Ablynx N.V. |
Polypeptides that modulate the interaction between cells of the immune system
|
|
EP2856876B1
(en)
|
2007-03-30 |
2018-01-31 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
US8114630B2
(en)
|
2007-05-02 |
2012-02-14 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
|
CA2693707A1
(en)
|
2007-07-13 |
2009-03-05 |
The Johns Hopkins University |
B7-dc variants
|
|
EP2612867A1
(en)
|
2007-11-01 |
2013-07-10 |
Perseid Therapeutics LLC |
Immunosuppressive polypeptides and nucleic acids
|
|
EP2250278B1
(en)
|
2008-02-21 |
2023-04-05 |
Burnham Institute for Medical Research |
Methods and compositions related to peptides and proteins with c-terminal elements
|
|
WO2009117622A2
(en)
|
2008-03-19 |
2009-09-24 |
Ambrx, Inc. |
Modified fgf-23 polypeptides and their uses
|
|
EP3605088A1
(en)
|
2008-04-09 |
2020-02-05 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
US7915222B2
(en)
|
2008-05-05 |
2011-03-29 |
Bristol-Myers Squibb Company |
Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis
|
|
JP2011524743A
(ja)
|
2008-06-02 |
2011-09-08 |
アンスティテュ・グスターブ・ルシ |
ナチュラルキラーｐ３０（ＮＫｐ３０）機能障害及びその生物学的用途
|
|
US9931386B2
(en)
|
2008-06-16 |
2018-04-03 |
Atsuo Ochi |
Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
|
|
EP2318029B1
(en)
|
2008-07-23 |
2017-11-01 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
|
US20110159023A1
(en)
|
2008-08-25 |
2011-06-30 |
Solomon Langermann |
Pd-1 antagonists and methods for treating infectious disease
|
|
EA023148B1
(ru)
|
2008-08-25 |
2016-04-29 |
Эмплиммьюн, Инк. |
Композиции на основе антагонистов pd-1 и их применение
|
|
EP2342223B1
(en)
|
2008-09-26 |
2017-04-26 |
Ambrx, Inc. |
Modified animal erythropoietin polypeptides and their uses
|
|
CA2751489A1
(en)
|
2009-02-04 |
2010-08-12 |
Board Of Regents, The University Of Texas System |
Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders
|
|
EP3381937A3
(en)
|
2009-08-13 |
2018-10-31 |
The Johns Hopkins University |
Methods of modulating immune function
|
|
EP2482849B1
(en)
|
2009-09-30 |
2018-06-06 |
Memorial Sloan-Kettering Cancer Center |
Combination immunotherapy for the treatment of cancer
|
|
US9540426B2
(en)
|
2009-10-06 |
2017-01-10 |
Bristol-Myers Squibb Company |
Mammalian cell culture processes for protein production
|
|
EP2504028A4
(en)
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
CA2791975C
(en)
|
2010-02-04 |
2021-02-09 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
US8329867B2
(en)
|
2010-02-19 |
2012-12-11 |
Xencor, Inc. |
CTLA4-Ig immunoadhesins
|
|
JP6066732B2
(ja)
|
2010-03-05 |
2017-01-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的免疫調節抗体および融合タンパク質に基づく組成物および方法
|
|
TW201134481A
(en)
|
2010-03-12 |
2011-10-16 |
Abbott Biotherapeutics Corp |
CTLA4 proteins and their uses
|
|
CN107090029B
(zh)
|
2010-11-11 |
2021-07-13 |
港大科桥有限公司 |
可溶性 pd-1变体、融合构建体及其用途
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
SMT201700025T1
(it)
|
2011-04-13 |
2017-03-08 |
Bristol Myers Squibb Co |
Proteine di fusione ad fc comprendenti nuovi raccordi o arrangiamenti
|
|
EP2697256A1
(en)
|
2011-04-15 |
2014-02-19 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
|
US8609625B2
(en)
|
2011-06-24 |
2013-12-17 |
Taipei Veterans General Hospital |
Method for enhancing immune response in the treatment of infectious and malignant diseases
|
|
BR112013033661A2
(pt)
*
|
2011-06-30 |
2017-01-24 |
Genzyme Corp |
inibidores de ativação de células t
|
|
US8956619B2
(en)
|
2011-10-25 |
2015-02-17 |
University Of Maryland, Baltimore County |
Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
|
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
MX366864B
(es)
|
2012-02-27 |
2019-07-26 |
Amunix Operating Inc |
Composiciones de conjugados de xten y métodos para realizarlas.
|
|
US9758566B2
(en)
|
2012-03-29 |
2017-09-12 |
The General Hospital Corporation |
Recombinant cytotoxic T-lymphocyte-associated protein 4 (CTLA4)
|
|
SG10201609447XA
(en)
|
2012-05-11 |
2017-01-27 |
Medimmune Llc |
Ctla-4 variants
|
|
EP2858673A4
(en)
|
2012-06-06 |
2016-06-22 |
Oncomed Pharm Inc |
BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
|
|
AU2013284460A1
(en)
|
2012-06-27 |
2015-01-29 |
Dmnomore |
CTLA4 fusion proteins for the treatment of diabetes
|
|
JP5857896B2
(ja)
|
2012-07-06 |
2016-02-10 |
東京エレクトロン株式会社 |
成膜装置の運転方法及び成膜装置
|
|
AR093788A1
(es)
|
2012-12-04 |
2015-06-24 |
Oncomed Pharm Inc |
Inmunoterapia con agentes de enlace
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
WO2014138188A1
(en)
|
2013-03-07 |
2014-09-12 |
The General Hospital Corporation |
Human ctla4 mutants and use thereof
|
|
GB201311475D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Polypeptides
|
|
WO2014207748A1
(en)
|
2013-06-27 |
2014-12-31 |
Alexander Biro |
Soluble ctla-4 molecules and derivatives thereof for treatment of minimal change disease
|
|
RU2702108C2
(ru)
|
2013-07-16 |
2019-10-04 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit
|
|
CN105916883B
(zh)
|
2014-01-28 |
2019-12-03 |
北京韩美药品有限公司 |
双功能融合蛋白及其制备方法和用途
|
|
WO2015120363A1
(en)
|
2014-02-10 |
2015-08-13 |
Emory University |
Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer
|
|
EP3134109A1
(en)
|
2014-04-25 |
2017-03-01 |
Bristol-Myers Squibb Company |
Use of ctla4 compound for achieving drug-free remission in subjects with early ra
|
|
EP3552615B8
(en)
|
2014-07-16 |
2022-03-02 |
Transgene |
Oncolytic virus for expression of immune checkpoint modulators
|
|
MX2016017288A
(es)
|
2014-07-16 |
2017-06-27 |
Genentech Inc |
Metodos para tratar el cancer con inhibidores de tigit y agentes contra el cancer.
|
|
ES2819451T3
(es)
|
2014-08-08 |
2021-04-16 |
Univ Leland Stanford Junior |
Agentes PD-1 de alta afinidad y procedimientos de uso
|
|
MX2017002791A
(es)
|
2014-09-03 |
2017-05-30 |
Bavarian Nordic As |
Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
|
|
US20160145344A1
(en)
|
2014-10-20 |
2016-05-26 |
University Of Southern California |
Murine and human innate lymphoid cells and lung inflammation
|
|
JP2018501302A
(ja)
|
2014-11-06 |
2018-01-18 |
チルドレンズ リサーチ インスティテュート、チルドレンズ ナショナル メディカル センター |
癌及び自己免疫疾患のための免疫療法剤
|
|
WO2016118577A1
(en)
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
JP6841812B2
(ja)
|
2015-04-02 |
2021-03-10 |
キャンキュア リミティド |
免疫応答を惹起するための作用物質及び組成物
|
|
WO2016164428A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Receptor-based antagonists of the programmed cell death 1 (pd-1) pathway
|
|
PT3283508T
(pt)
|
2015-04-17 |
2021-06-21 |
Alpine Immune Sciences Inc |
Proteínas imuno modulatórias com afinidades afináveis
|
|
TWI715587B
(zh)
|
2015-05-28 |
2021-01-11 |
美商安可美德藥物股份有限公司 |
Ｔｉｇｉｔ結合劑和彼之用途
|
|
MX2017015041A
(es)
|
2015-05-29 |
2018-02-26 |
Squibb Bristol Myers Co |
Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos.
|
|
SG10202010506TA
(en)
|
2015-07-30 |
2020-11-27 |
Macrogenics Inc |
Pd-1-binding molecules and methods of use thereof
|
|
CA2993478A1
(en)
|
2015-07-31 |
2017-02-09 |
Tarveda Therapeutics, Inc. |
Compositions and methods for immunomodulation
|
|
EP3328377A4
(en)
|
2015-07-31 |
2019-03-13 |
Tarveda Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR IMMUNE ONCOLOGY THERAPIES
|
|
JP6859320B2
(ja)
|
2015-08-20 |
2021-04-14 |
フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． |
臓器不全の治療および予防用のｂ７−ｈ１融合ポリペプチド
|
|
KR20180054713A
(ko)
|
2015-09-14 |
2018-05-24 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
조율가능한 변종 면역글로불린 수퍼패밀리 도메인 및 유전자 조작된 세포 치료법
|
|
JP6875385B2
(ja)
|
2015-10-02 |
2021-05-26 |
シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ |
抗ｐｄ−１抗体および組成物
|
|
EP3371208B8
(en)
|
2015-11-02 |
2024-10-23 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides and their use in cancer treatment
|
|
EP3371210B1
(en)
|
2015-11-04 |
2022-05-25 |
Taipei Veterans General Hospital |
Combination therapy for malignant diseases
|
|
US10954301B2
(en)
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
CA3014458A1
(en)
|
2016-03-02 |
2017-09-08 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
IL310729A
(en)
|
2016-04-15 |
2024-04-01 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
WO2017181148A2
(en)
|
2016-04-15 |
2017-10-19 |
Alpine Immune Sciences, Inc. |
Icos ligand variant immunomodulatory proteins and uses thereof
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
CA3040504A1
(en)
|
2016-10-14 |
2018-04-19 |
Xencor, Inc. |
Il15/il15ra heterodimeric fc-fusion proteins
|
|
EP3872180A1
(en)
|
2016-10-20 |
2021-09-01 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
WO2018170021A1
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Pd-l1 variant immunomodulatory proteins and uses thereof
|
|
US11732022B2
(en)
|
2017-03-16 |
2023-08-22 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
IL268781B2
(en)
|
2017-03-16 |
2025-09-01 |
Alpine Immune Sciences Inc |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
CA3198255A1
(en)
|
2017-10-10 |
2019-04-18 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
EA202090974A1
(ru)
|
2017-10-18 |
2020-08-05 |
Элпайн Иммьюн Сайенсиз, Инк. |
Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
|
|
WO2019136179A1
(en)
|
2018-01-03 |
2019-07-11 |
Alpine Immune Sciences, Inc. |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020061376A2
(en)
|
2018-09-19 |
2020-03-26 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
|
US20240209061A1
(en)
|
2020-03-09 |
2024-06-27 |
Pfizer Inc. |
Fusion proteins and uses thereof
|
|
EP4490173A1
(en)
|
2022-03-07 |
2025-01-15 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|